MAP
URGN icon

Moody Aldrich Partners’s UroGen Pharma URGN Stock Holding History

Moody Aldrich Partners’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-18,200
Closed -$860K – 111
2018
Q3 		$860K Buy
+18,200
New +$846K 0.25% 88

Other funds holding URGN

MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HCM
Highline Capital Management New York $53.5M AUM 21.72% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $14.9B AUM 46.8% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Moody Aldrich Partners's URGN Position: Q4 2018 in Review

Moody Aldrich Partners sold out of UroGen Pharma (URGN) in Q4 2018, closing a stake of 18,200 shares — an estimated $860K sold.

Moody Aldrich Partners first reported a position in URGN in Q3 2018 and held it in 1 quarter. The position peaked at $860K in Q3 2018. 63 funds tracked by Wall St. Rank hold URGN as of Q4 2018.

  • Moody Aldrich Partners reported no remaining UroGen Pharma position as of Q4 2018 after selling out during the quarter.
  • Moody Aldrich Partners sold 18,200 UroGen Pharma shares in Q4 2018, an estimated $860K.
  • Moody Aldrich Partners first reported a position in UroGen Pharma in Q3 2018 and held it in 1 quarter.
  • Moody Aldrich Partners's UroGen Pharma position peaked at $860K in Q3 2018.
  • 63 funds tracked by Wall St. Rank held UroGen Pharma as of Q4 2018.

Based on Moody Aldrich Partners's 13F filing for Q4 2018, filed 12 Feb 2019.